Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7628-7639

  Song, Siyuan ^a   Christova, Tania ^a   Perusini, Stephen ^a   Alizadeh, Solmaz ^b   Bao, Ren Yue ^a,h   Miller, Bryan W ^a   Hurren, Rose ^c   Jitkova, Yulia ^c   Gronda, Marcela ^c   Isaac, Methvin ^d   Joseph, Babu ^d   Subramaniam, Ratheesh ^d   Aman, Ahmed ^d   Chau, Anh ^d   Hogge, Donna E ^e   Weir, Scott J ^f   Kasper, James ^g   Schimmer, Aaron D ^c   Al Awar, Rima ^d   Wrana, Jeff L ^b   Attisano, Liliana ^a   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^f UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^g The Leukemia & Lymphoma Society   (United States)

^h ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLHYDRAZONE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA CATENIN; CALCEIN; CICLOPIROXOLAMINE; DEFERASIROX; DEFEROXAMINE; GLUTATHIONE TRANSFERASE; IRON; IRON CHELATING AGENT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UVOMORULIN; WNT INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AXIN2 GENE; CANCER CELL; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; GENE; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; IC 50; IMMUNOBLOTTING; IN VITRO STUDY; IRON CHELATION; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ADMINISTRATION, ORAL; BENZOIC ACIDS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DEFEROXAMINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYDRAZONES; IRON; IRON CHELATING AGENTS; LEUKEMIA, MYELOID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PYRIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84255199531     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2745     Document Type: Article

References (39)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
2. Turashvili G, Bouchal J, Burkadze G, Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 2006;73:213-23. (Pubitemid 46332829)
3. Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18:523-7. (Pubitemid 351630946)
4. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A 2009;106:3396-401.
5. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006;20:1211-6. (Pubitemid 43905823)
6. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010;327:1650-3.
7. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014. (Pubitemid 44835127)
8. Janssens N, Janicot M, Perera T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs 2006;24:263-80.
9. Chen B, Dodge ME, Tang W, Lu J,MaZ, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
10. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
11. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010;6:829-36.
12. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Rahmanto YS, Sharpe PC, et al. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 2011;11:483-99.
13. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009;1790:702-17.
14. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006;2:406-14. (Pubitemid 44114917)
15. Torti SV, Torti FM. Ironing out cancer. Cancer Res 2011;71:1511-4.
16. Chang M, Kanwar N, Feng E, Siu A, Liu X, Ma D, et al. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther 2010;9:2478-87.
17. Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, et al. Transcriptional cooperation between the transforming growth factorbeta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 2007;67:75-84. (Pubitemid 46142761)
18. Miller BW, Lau G, Grouios C, Mollica E, Barrios-Rodiles M, Liu Y, et al. Application of an integrated physical and functional screening approach to identify inhibitors of the Wnt pathway. Mol Syst Biol 2009;5:315.
19. Christova T, Templeton DM. Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteins. Mol Cell Biochem 2007;301:21-32. (Pubitemid 46895143)
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12. (Pubitemid 20213250)
21. Winer IS, Bommer GT, Gonik N, Fearon ER. Lysine residues Lys-19 and Lys-49 of beta-catenin regulate its levels and function in T cell factor transcriptional activation and neoplastic transformation. J Biol Chem 2006;281:26181-7. (Pubitemid 44401825)
22. Richardson D, Baker E. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J Biol Chem 1992;267:13972-9.
23. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 1997;248:31-40. (Pubitemid 27218221)
24. Ternes N, Scheiber-Mojdehkar B, Landgraf G, Goldenberg H, Sturm B. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant 2007;22:2824-30. (Pubitemid 350093433)
25. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
26. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006;281:17751-7. (Pubitemid 44035574)
27. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-9. (Pubitemid 43089612)
28. Saletta F, Rahmanto YS, Noulsri E, Richardson DR. Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol 2010;77:443-58.
29. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7:345-50. (Pubitemid 32735019)
30. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72. (Pubitemid 46660978)
31. Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron (III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem 1999;4:266-73. (Pubitemid 29331015)
32. Ihnat PM, Vennerstrom JL, Robinson DH. Synthesis and solution properties of deferoxamine amides. J Pharm Sci 2000;89:1525-36.
33. Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 2001;7:3574-9. (Pubitemid 33069997)
34. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009;114:3064-73.
35. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-8. (Pubitemid 32783265)
36. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50. (Pubitemid 35292444)
37. Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchin NA, Matthews G, et al. A role for iron in Wnt signalling. Oncogene 2008;27:966-75. (Pubitemid 351225389)
38. Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 2011 Jun 13 [Epub ahead of print].
39. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010;2:43ra56.